Belite Bio Posts Q2 Results, Completes Enrollment in Two Pivotal Trials
BLTE has more than doubled off its 52-week low of $60.
Summary
Belite Bio reported Q2 2026 financials with $279.9M cash and $500.1M in treasury investments, providing runway into the PDUFA date of February 12, 2027 for tinlarebant in Stargardt disease. R&D expenses rose to $18.2M for the quarter, driven by a milestone royalty payment, and the Q2 net loss widened on higher expenses. The company also completed enrollment in the DRAGON II trial (73 subjects) and the PHOENIX trial in geographic atrophy (530 subjects), with an interim analysis expected for PHOENIX. This follows the FDA's Priority Review acceptance announced two days ago, and management is planning a Commercial Day in September to outline launch preparations.
At the time of this announcement, BLTE was trading at $178.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $60.00 to $200.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.